Stocks in Focus: Eli Lilly & Co., Immersion Corporation, Alcatel Lucent, Inovio Pharmaceuticals

Lakeway, TX -- (SBWIRE) -- 03/07/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Eli Lilly & Co. (NYSE:LLY) went up 0.71% to $55.47 on a traded volume of 1.20 million shares. Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company announced results of a study evaluating the efficacy of LIVALO 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol in HIV-infected adults with high cholesterol, or dyslipidemia. The study was designed as a superiority trial for the primary endpoint, percent reduction in LDL-C, and evaluated HIV-infected adults with dyslipidemia; with and without viral Hepatitis B or C. The study met its primary endpoint.

How Should Investors Trade LLY After The Recent Movement? Find Out Here

Immersion Corporation (NASDAQ:IMMR) augmented 41.47% to $8.87 on a traded volume of 1.33 million shares. The Company has entered into a multi-year license agreement with Samsung Electronics Co., Ltd. In addition to providing a license to Immersion's TouchSense and Integrator solutions, the agreement includes a patent license covering Samsung's prior and future use of simple forms of haptic effects in its smartphones and other mobile devices.

Is IMMR Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Alcatel Lucent SA (ADR)(NYSE:ALU) sahres increased 2.82% to $1.46. The company last month announced that its Board of Directors has approved the appointment of Mr. Michel Combes as the Company’s new Chief Executive Officer, effective April 1, 2013.

Additionally, Sequans Communications S.A. (NYSE:SQNS) announced last month that it has successfully completed interoperability testing of Alcatel-Lucent's LTE infrastructure equipment with Sequans' eMBMS-capable LTE chipsets.

Is ALU a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) shares declined 23.27% to $0.530 after the company today priced an underwritten offering of 27,377,266 shares of its common stock and warrants to purchase up to 13,688,633 shares of common stock at a combined price to the public of $0.55 per share and related warrant for gross proceeds of $15.1 million. The warrants are exercisable at an exercise price of $.7936 per share and will expire, unless exercised, on the date that is 180 days after the fifth anniversary of the date of issuance.

How Should Investors Trade INO After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.